Eloxx Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Eloxx Pharmaceuticals's earnings have been declining at an average annual rate of -10.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
-10.9%
Earnings growth rate
32.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Eloxx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -42 | 13 | 27 |
| 30 Jun 22 | 0 | -44 | 15 | 28 |
| 31 Mar 22 | 0 | -70 | 19 | 26 |
| 31 Dec 21 | 0 | -67 | 21 | 22 |
| 30 Sep 21 | 0 | -61 | 19 | 17 |
| 30 Jun 21 | 0 | -57 | 18 | 15 |
| 31 Mar 21 | 0 | -29 | 15 | 13 |
| 31 Dec 20 | 0 | -35 | 15 | 14 |
| 30 Sep 20 | 0 | -40 | 18 | 18 |
| 30 Jun 20 | 0 | -46 | 21 | 21 |
| 31 Mar 20 | 0 | -53 | 24 | 25 |
| 31 Dec 19 | 0 | -51 | 24 | 26 |
| 30 Sep 19 | 0 | -53 | 26 | 27 |
| 30 Jun 19 | 0 | -52 | 26 | 25 |
| 31 Mar 19 | 0 | -51 | 29 | 22 |
| 31 Dec 18 | 0 | -47 | 26 | 20 |
| 30 Sep 18 | 0 | -45 | 20 | 22 |
| 30 Jun 18 | 0 | -38 | 15 | 20 |
| 31 Mar 18 | 0 | -29 | 6 | 18 |
| 31 Dec 17 | 0 | -24 | 3 | 16 |
| 30 Sep 17 | 0 | -16 | 2 | 11 |
| 31 Dec 16 | 0 | -11 | 1 | 9 |
Quality Earnings: 397 is currently unprofitable.
Growing Profit Margin: 397 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 397 is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare 397's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 397 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 397's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.